Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

89 questions · 89 findings · 7 reviews

No studies found 8 · 9%GRADE not reported 0 · 0%Very low 17 · 19.1%Low 33 · 37.1%Moderate 31 · 34.8%High 0 · 0%

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Graft loss: late withdrawal · kidney transplant recipients

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: late withdrawal compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review